Uric Acid, Vascular Stiffness, and Chronic Kidney Disease: Is There a Link?

Juan C. Ramirez-Sandoval \textsuperscript{a} L. Gabriela Sanchez-Lozada \textsuperscript{b} Magdalena Madero \textsuperscript{b}

\textsuperscript{a}Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ)), and \textsuperscript{b}Instituto Nacional de Cardiología Ignacio Chávez (National Heart Institute), Mexico City, Mexico

Introduction

Hyperuricemia is a very common biochemical finding associated with aging, hypertension, chronic kidney disease (CKD), and cardiovascular disease (CVD) [1]. Nevertheless, the evidence for a causal link between hyperuricemia and these disorders is controversial, and it has not been firmly established [2]. Particularly, hyperuricemia in persons with CKD appears to be associated with an increased risk for cardiovascular and all-cause-mortality, but the role of serum uric acid (SUA) in the initiation, progression, and development of kidney failure remains questionable [3].

Arterial stiffness could be one of the possible mechanisms by which hyperuricemia increases the risk of CKD and CVD through a pathway that involves changes in vascular elastic properties, hypertension and organ damage [4]. This review summarizes relevant studies concerning SUA and vascular stiffness and possible links to the pathogenesis and progression of CKD.

Vascular Stiffness as the Link between Hyperuricemia and CKD

Arterial stiffness may be an early marker of CVD, as it predicts cardiovascular events in patients with essential hypertension and CKD [5]. Because large-vessel arterial stiffness is common in CKD, it is believed to be one of the
mechanisms accounting for the increased risk of CVD in CKD. Vascular stiffness, independent of mean arterial pressure, establishes end-organ damage by increasing the recruitment of collagen fibers and progressive elastic fiber degeneration [6]. The stiffening process facilitates the transmission of excessive pressure and flow pulsatility, which may damage microcirculation, especially in a high-flow organ such as the kidney, leading to potentially microvascular ischemia and tissue damage [7]. Systemic pulsatile pressure can cause vascular injury in low-resistance, high-flow end organs, such as the kidney and brain [8]. There are different mechanisms suggesting a causal role of arterial stiffness in CKD. A possible hypothesis is that the changes in hemodynamic stress on the kidney vasculature may result in endothelial inflammation, infiltration of vascular smooth muscle cells and macrophages, fibrosis, deposition of mucoid material, focal media smooth muscle cell necrosis and vascular calcification [9, 10]. Other plausible mechanisms are related to the effects of chronic inflammation and activation of the renin-angiotensin system [11].

Vascular stiffness is usually estimated using the arterial pulse wave velocity (aPWV) between 2 predefined sites of the arterial system such as carotid-femoral, carotid-radial, or carotid-ankle; the time delay of the arrival of the foot of the pulse wave at these 2 sites is obtained by gating to the R wave of the ECG. Figure 1 shows aPWV in healthy vessels and in vascular stiffness [12]. Different cut-off values have been proposed according to the type of aPWV [13]; unfortunately, a clear international nomenclature is not commonly used, and so analysis and comparison between studies cannot be carried out with ease. Other measurements such as aortic augmentation index (AI) may not be the ideal parameter of arterial stiffness as aPWV, since it is modified by left ventricular ejection fraction and heart rate [14]. Pulse pressure, which is the difference between systolic and diastolic pressures, is one of the simplest measures of vascular stiffness, but it is inaccurate, given the problems related to the normal amplification of the pressure wave and that assessment of pulse pressure in the periphery does not reflect the actual central pulse pressure [15].

Fig. 1. Estimation of PWV in healthy individuals and in those who have hyperuricemia-induced vascular stiffness (see text for details).
Several observational studies have demonstrated the association of vascular muscle stiffness with decline in kidney function [8, 16–18]. Since aortic stiffness is highly prevalent in CKD and predicts CVD events and SUA is associated with vascular disease, the relationship between UA and vascular disease could explain in part the association between the vascular stiffness and CKD.

**SUA and Vascular Disease: Mechanisms of Disease**

SUA may have a role in the initiation of vascular stiffness and, therefore, also a role in causing vascular disease, hypertension, and CKD. The occurrence of vascular disease may be explained by the following mechanisms: (i) uric acid gains entry to vascular endothelial cell and vascular smooth muscle cells through urate-anion exchangers such as URAT-1, which is expressed in endothelial cells and not only in kidney tubular cells [19]; (ii) high uric acid in the intracellular compartment induces several mechanisms of cellular damage by increasing the activity of nicotinamide adenine dinucleotide phosphate oxidase, which produces reactive oxygen-species and decreases the bioavailability of nitric oxide (NO) [20]; (iii) uric acid activates the transcription factors nuclear factor-κB, activator protein-1, the mitogen-activated protein kinase signaling molecules ERK p44/42 and p38, and increases cyclooxygenase-2 mRNA expression in cultured vascular smooth-muscle cells [21]; (iv) oxidative stress induced by uric acid also activates the Notch-1 pathway in a dose- and time-dependent manner, which plays an important role in inflammation [22]; (v) uric acid stimulates increased production of the chemokine monocyte chemoattractant protein 1 (MCP-1) expression in a time- and dose-dependent manner dependent on posttranscriptional modification of MCP-1 mRNA [21]; (vi) urate-induced oxidative stress increases the production of potent vasoconstrictors such as endothelin-1 [23]; (vii) uric acid stimulates the local vascular renin-angiotensin system through the activation of mitogen-activated protein (MAP) kinase pathway. The activation of the renin-angiotensin system and reduction of NO synthesis promotes endothelial dysfunction [24]. All these inflammatory pathways may play a role in the process of arterial stiffening even in health; (viii) arterial stiffness relies on the structural properties of the large artery wall, including its essential protein, elastin. Polymers of elastin are the major extracellular matrix components deposited mainly by vascular smooth muscle cells in the arterial media providing ‘elasticity’ to the aorta and resilience against the hemodynamic stresses of the distending pressure [25]. Hyperuricemia may affect the natural turnover of non-cross-linked soluble elastin, a potential indicator of eventual vascular stiffness [26]. Finally, in the kidney, hyperuricemia-induced microvascular damage to afferent arterioles may lead to the occurrence of sodium-sensitive hypertension [27]. In this condition, increased hypertension would induce more vascular stiffness that would increase blood pressure, which would become a vicious circle with time.

**UA and Vascular Stiffness: Observational Studies**

Numerous epidemiological studies have described a link between hyperuricemia and CVD. Recently, Borghi et al. [28] conducted a comprehensive review of hyperuricemia and cardiovascular morbidity and/or mortality; however, most of these studies did not include vascular stiffness as a surrogate endpoint. To define the role of SUA in vascular stiffness, we summarized observational studies that report an association between vascular stiffness and hyperuricemia (table 1). Four large epidemiological transversal studies including more than 1,000 patients with differences in clinical characteristics showed a positive association between SUA and vascular stiffness, assessed for the most part by carotid-femoral PWV (cfPWV) [29–32]. In one study from Framingham Heart Study Gen III Cohort, each 1 mg/dl increase in SUA was associated with higher cfPWV) [29]. Most of the studies that did not find an association in healthy individuals or in subjects without a history of CKD, CVD, or diabetes. The possible explanation behind these apparently discrepant findings may be that hyperuricemia is a stronger risk factor for vascular stiffness only if a second ‘hit’ has occurred. Several difficulties in determining whether SUA per se should be considered a causal factor for vascular stiffness since most of the studies had a cross-transversal design with potential residual confounding. To our knowledge, there are no cohort studies where the exposure (‘hyperuricemia’) could be assessed prior to the occurrence of vascular stiffness or CKD.

**UA and Vascular Disease: Interventional Studies**

Three parallel randomized, double-blind studies have tested the effect of allopurinol in vascular stiffness in subjects with stage 3 CKD [33], diabetes mellitus [34], and patients with ischemic heart disease (IHD) without CKD [35]. In each of these studies, 67 or 66 patients were assigned to allopurinol 600 mg/day for 9 months vs. placebo. Treat-
Table 1. Observational studies with a positive association between SUA and arterial stiffness

<table>
<thead>
<tr>
<th>Author (reference), year</th>
<th>Population</th>
<th>Country</th>
<th>Type of study</th>
<th>Serum SUA, mg/dl, mean ± SD or median (IQR)</th>
<th>eGFR, ml/min/1.73 m²</th>
<th>Vascular stiffness</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Studies with a positive association</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tausche et al. [36], 2014</td>
<td>17 (allopurinol, n = 8; febuxostat, n = 9)</td>
<td>Germany</td>
<td>Clinical trial</td>
<td>Baseline: 8 (not SD data), after 1 year: 5.0±0.8 and 4.8±1.6 for allopurinol and febuxostat respectively</td>
<td>No data</td>
<td>A significant cPWV increase was observed in the allopurinol group (14.1±3.4 to 16.8±4.3 m/s), but not in the febuxostat patients (13.7±2.7 to 13.3±2.3 m/s, p = 0.55)</td>
</tr>
<tr>
<td>Rekhraj et al. [35], 2013</td>
<td>59 (allopurinol, n = 31; placebo, n = 29)</td>
<td>United Kingdom</td>
<td>Clinical trial</td>
<td>Baseline: 9.9±1.5 and 9.4±2.4 for allopurinol and placebo respectively</td>
<td>No data, but eGFR &lt;30 ml/min/1.73 m² were excluded</td>
<td>Allopurinol reduced left ventricular end systolic volume, improved FMD and augmentation index</td>
</tr>
<tr>
<td>Mehta et al. [29], 2015 (Framingham heart study gen III participants)</td>
<td>1,992 men and 2,265 women</td>
<td>United States</td>
<td>Cross-sectional</td>
<td>5.3±1.5</td>
<td>104±21</td>
<td>Positive association with a multivariate adjusted means of cPWV of 6.90, 6.94, 7.06, and 7.15 m/s for uric acid quartile 1, 2, 3, and 4, respectively</td>
</tr>
<tr>
<td>Kuo et al. [30], 2010</td>
<td>5,074 men and 4,301 women</td>
<td>Taiwan</td>
<td>Cross-sectional</td>
<td>No data (14.5% had hyperuricemia defined as UA &gt;6.8-men or &gt;5.5-women)</td>
<td>No data but proteinuria was more frequent with hyperuricemia (9.3 vs. 2.8%)</td>
<td>Subjects with hyperuricemia had a significantly higher baPWV (1,618.8 (379.3) cm/s) than those without it (1,501.8 (334.9) cm/s). Hyperuricemia was a risk factor for abnormal baPWV (OR 1.89)</td>
</tr>
<tr>
<td>Park et al. [38], 2012</td>
<td>841 postmenopausal women</td>
<td>Korea</td>
<td>Cross-sectional</td>
<td>4.55±0.95</td>
<td>No data but CKD were excluded</td>
<td>PWV increased according to tertiles of SUA; cPWV (β = 0.129, p &lt; 0.01) were independently correlated with SUA after adjusting for risk factors</td>
</tr>
<tr>
<td>Zhang et al. [39], 2014</td>
<td>100 men with DM2</td>
<td>China</td>
<td>Cross-sectional</td>
<td>5.62</td>
<td>No data but CKD excluded</td>
<td>SUA was correlated with cPWV (r = 0.533, p = 0.001) and crPWV (r = 0.334, p = 0.001)</td>
</tr>
<tr>
<td><strong>Studies with a mixed result</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kao et al. [33], 2011</td>
<td>53 (allopurinol, n = 27; placebo, n = 26)</td>
<td>United Kingdom</td>
<td>Clinical trial</td>
<td>Baseline: 7.4±1.5 and 7.1±1.3 for allopurinol and placebo respectively</td>
<td>44±11 and 46±9 for allopurinol and placebo respectively</td>
<td>There were no changes in PWV at 9 months even significant regression of left ventricular mass and improved the augmentation index were observed in the allopurinol group</td>
</tr>
<tr>
<td>Szwejkowski et al. [34], 2013</td>
<td>59 (allopurinol, n = 29; placebo, n = 30)</td>
<td>United Kingdom</td>
<td>Clinical trial</td>
<td>Baseline: 9.7±2.2</td>
<td>86.31±13.75</td>
<td>No significant changes were seen in augmentation index but a significant regression of left ventricular mass was observed</td>
</tr>
<tr>
<td>Fang et al. [31], 2014</td>
<td>2,968 men and 2,182 women</td>
<td>Taiwan</td>
<td>Cross-sectional</td>
<td>UA was 4.6±0.9 and 5.0±1.2 for baPWV &lt; and &gt;1,400 cm/s, respectively</td>
<td>No data but eGFR &lt;30 ml/min/1.73 m² were excluded</td>
<td>Only women with upper tertiles of SUA had greater baPWV level. No association was found in men</td>
</tr>
<tr>
<td>Gu et al. [32], 2012</td>
<td>1,138 men and 1,236 women</td>
<td>China</td>
<td>Cross-sectional</td>
<td>5.5±1.2 in men, 4.4±1.1 in women</td>
<td>No data but CKD excluded</td>
<td>Only serum SUA was independently associated with cPWV in women. No independent association was found between SUA and crPWV or caPWV in both genders</td>
</tr>
</tbody>
</table>
### Table 1. (continued)

<table>
<thead>
<tr>
<th>Author (reference), year</th>
<th>Population</th>
<th>Country</th>
<th>Type of study</th>
<th>Serum SUA, mg/dl, mean ± SD or median (IQR)</th>
<th>eGFR, ml/min/1.73 m²</th>
<th>Vascular stiffness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomiyama et al. [40], 2003</td>
<td>4,488 men and 3,393 women, Japan</td>
<td>Cross-sectional</td>
<td>6.0±1.2 in men, 4.4±0.9 in women</td>
<td>No data but CKD excluded</td>
<td>Age and blood pressure variables were potent significant variables for baPWV, and body mass index, triglycerides, SUA, and fasting blood sugar were significant but weak variables for baPWV in both genders.</td>
<td></td>
</tr>
<tr>
<td>Elsurer et al. [41], 2014</td>
<td>147 men and 192 women, Turkey</td>
<td>Cross-sectional</td>
<td>No data</td>
<td>No data but all with CKD (most in CKD stages 2 and 3)</td>
<td>SUA was associated significantly with PWV only in women</td>
<td></td>
</tr>
<tr>
<td>Fu et al. [42], 2015</td>
<td>623 men and 917 women, China</td>
<td>Cross-sectional</td>
<td>4.8 (4.0–5.7)</td>
<td>87.5 (IQR 78.7–97.0)</td>
<td>SUA was associated with PWV only in women</td>
<td></td>
</tr>
<tr>
<td>Lim et al. [43], 2010</td>
<td>693 men and 583 women, Korea</td>
<td>Cross-sectional</td>
<td>5.2±1.4 (6.0±1.3 in men and 4.3±0.9 in women)</td>
<td>No data but CKD excluded</td>
<td>SUA was not associated with baPWV and hPWV</td>
<td></td>
</tr>
<tr>
<td>Tsiofis et al. [44], 2011</td>
<td>191 men and 101 women, Greece</td>
<td>Cross-sectional</td>
<td>5.2 (no data on IQR)</td>
<td></td>
<td>UA was associated with PWV only in women</td>
<td></td>
</tr>
<tr>
<td>Alvim et al. [45], 2010</td>
<td>678 men and 783 women, Brazil</td>
<td>Cross-sectional</td>
<td>SUA according to APOE polymorphism: 5.0±1.6 for APOE ε4, 4.7±1.6 for ε2 and 4.8±1.5 for ε3</td>
<td>No data but mean serum creatinine was 0.99±0.20 mg/dl</td>
<td>cPWV was not different in patients with more hyperuricemia and APOE ε4 (9.8±2.1 m/s) compared with polymorphism ε2 (10.0±2.1 m/s) and ε3 (9.8±2.2 m/s)</td>
<td></td>
</tr>
<tr>
<td>Cicero et al. [46], 2014</td>
<td>248 men and 371 women, Italy</td>
<td>Cross-sectional</td>
<td>4.8±1.5 (5.7±1.4 in men, 4.2±1.2 in women)</td>
<td>68.1±6.2</td>
<td>A significant association between SUA and cPWV was found in univariate analysis but when adjusting for age, the trend became nonsignificant</td>
<td></td>
</tr>
<tr>
<td>Li et al. [47], 2014</td>
<td>562 men and 681 women, China</td>
<td>Cross-sectional</td>
<td>5.6±1.4 (6.1±1.3 in men, 5.2±1.3 in women)</td>
<td>No data</td>
<td>UA had an independent association with peripheral artery disease in men but not with cardioankle vascular index</td>
<td></td>
</tr>
<tr>
<td>Mulè et al. [48], 2014</td>
<td>133 men and 89 women, Italy</td>
<td>Cross-sectional</td>
<td>5.4±1.3</td>
<td>103.5±10</td>
<td>cPWV was significantly higher in hypertensive patients belonging to the uppermost tertile of UA distribution but this in multiple regression model</td>
<td></td>
</tr>
<tr>
<td>Sabio et al. [49], 2010</td>
<td>102 women with systemic lupus erythematosus, Spain</td>
<td>Cross-sectional</td>
<td>4.3 (IQR 3.7–5.4)</td>
<td>No data but CKD were excluded</td>
<td>UA was associated with arterial stiffness, but not independently of age and homocysteine levels</td>
<td></td>
</tr>
<tr>
<td>Cipolli et al. [50], 2012</td>
<td>131 men and 207 women, Brazil</td>
<td>Cross-sectional</td>
<td>6.7±0.2 in men, 5.4±0.1 in women</td>
<td>99.0±2.4 and 87.9±3.0 in men and women, respectively</td>
<td>UA was associated with internal carotid artery resistive index only in women but not associated with other ultrasound parameters including stiffness index</td>
<td></td>
</tr>
</tbody>
</table>

IQR = Interquartile range; eGFR = estimated glomerular filtration rate; cPWV = carotid-radial PWV; baPWV = brachial ankle PWV; hPWV = heart femoral PWV; CAVI = cardio-ankle vascular index; FMD = flow-mediated dilation; APOE = apolipoprotein E.
ment with allopurinol had a small but significant regression of left ventricular mass, but there were no changes in PWV at 9 months in CKD or IHD patients. Nevertheless, allopurinol significantly reduced AI in CKD and IHD patients, which was statistically significant at 9 months. The authors suggest that allopurinol caused a significant reduction in AI and improved endothelial function without a significant effect on BP suggesting improved arterial compliance [35]. It has been demonstrated that different medications to lower SUA have varied effects on vascular stiffness. In a 1-year prospective comparative study, patients with gout assigned to allopurinol had a significant increase in cPWBV (16.8 ± 4.3 m/s, p = 0.001 as compared to baseline), but febuxostat-treated patients experienced a beneficial yet opposite effect (3.3 m/s, p = 0.001 as compared to baseline), although both medications inhibited xanthine oxidase and resulted in effective reduction in SUA levels [36]. One small study of 10 patients with diabetes mellitus and 10 healthy controls did not find any changes in cPWB or AI after a rapid infusion of intravenous urate oxidase, although SUA decreased significantly [37]. The small and inconclusive evidence from these interventional trials calls for further studies.

**Perspective and Conclusion**

Vascular stiffness provides a better understanding of the relationship between SUA, CKD and CVD. Further research is clearly required in order to establish the effect of lowering SUA on cardiovascular and renal endpoints. In this regard, vascular stiffness assessed with PWV may be a reproducible, valid, short-term, and useful surrogate endpoint. Although there is a clear and proposed link between SUA and vascular stiffness, it does not yet support the specific treatment of hyperuricemia to reduce kidney or cardiovascular outcomes. Nevertheless, there would seem to be sufficient evidence to warrant larger clinical trials to determine whether lowering SUA concentrations would be useful in the prevention or treatment of vascular stiffness and, subsequently, of cardiovascular and renal diseases.

**Disclosure Statement**

The authors have no financial conflicts of interest to declare.

**References**

Hyperuricemia, Vascular Stiffness and CKD

BMC Cardiovasc Disord 2012;12:52

DOI: 10.1159/000452726


